Sigilon Announces Reverse Stock Split of Common Stock
22 mai 2023 07h30 HE
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common...
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
09 mai 2023 07h30 HE
|
Sigilon Therapeutics, Inc.
SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023 Pipeline prioritization extends anticipated cash runway into...
Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference
18 avr. 2023 07h00 HE
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through...
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
14 mars 2023 16h15 HE
|
Sigilon Therapeutics, Inc.
Advancing IND-enabling activities for lead program in diabetes, SIG-002, with plans to conduct non-human primate studies in second half of 2023 SIG-002 demonstrated efficacy and durability in in vivo...
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
10 nov. 2022 07h30 HE
|
Sigilon Therapeutics, Inc.
Identified important optimization features for its platform to mitigate PFO risks in current and future programs Advanced iPS cell differentiation protocol for the diabetes program in preparation...
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
04 août 2022 16h30 HE
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
Sigilon Therapeutics Reports First Quarter 2022 Financial Results And Business Highlights
12 mai 2022 16h05 HE
|
Sigilon Therapeutics, Inc.
On track to announce results from preclinical studies of SIG-005 in second half of 2022 Current cash position expected to fund operating plans into 2024 CAMBRIDGE, Mass., May 12, 2022 (GLOBE...
Sigilon Therapeutics to Present at the Needham Healthcare Conference
07 avr. 2022 07h00 HE
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
14 mars 2022 16h15 HE
|
Sigilon Therapeutics, Inc.
Announced strategic reprioritization, with plans to advance mucopolysaccharidosis type I (MPS-1) and diabetes as lead indications as well as continued platform optimization Strengthened leadership...
Sigilon Therapeutics to Present at the Barclays Global Healthcare Conference
08 mars 2022 07h00 HE
|
Sigilon Therapeutics, Inc.
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its...